New oncology strategy: molecular targeting of cancer cells.
Capriotti
Teri
T
Villanova University, College of Nursing, Villanova, PA, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D000068818:Cetuximab; D003546:Cysteine Endopeptidases / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D000077156:Gefitinib; D005826:Genetics, Medical / Q000379:methods* / Q000639:trends; D006801:Humans; D008495:Medical Oncology / Q000379:methods* / Q000639:trends; D008967:Molecular Biology / Q000379:methods* / Q000639:trends; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics; D024802:Nurse's Role; D009859:Oncology Nursing / Q000379:methods; D011480:Protease Inhibitors / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex; D011719:Pyrazines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; D009097:Multienzyme Complexes; D011480:Protease Inhibitors; D011719:Pyrazines; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D000069286:Bortezomib; D066246:ErbB Receptors; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000068878:Trastuzumab; D000068818:Cetuximab; D000077156:Gefitinib